Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start

Executive Summary

Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?

You may also be interested in...



Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There

Mylan's Herceptin biosimilar faces questions on off-label use and manufacturing, while Amgen's Avastin biosimilar could be template for other products.

Mylan's Herceptin Advisory Committee May Be First Bumpy One For A Biosimilar

US FDA did not address production problems in its briefing document for upcoming Oncologic Drugs Advisory Committee meeting, but manufacturing deficiencies found at Biocon's facility could prompt questions.

Amgen's Avastin Biosimilar May Revive Orphan Indication Concerns

Questions about US FDA's handling of orphan indications may arise again during upcoming Oncologic Drugs Advisory Committee meeting on ABP215, a proposed Avastin biosimilar.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel